Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Product type
Topic
- COVID-19 (81)
- Advertising (66)
- Labelling and packaging (10)
- Vaping hub (8)
- Legislation (7)
- Safety monitoring and information (4)
- Compliance and enforcement (3)
- Manufacturing (3)
- Medicinal cannabis hub (3)
- Scheduling (national classification system) (2)
- Committees and advisory bodies (1)
- Import and export (1)
- Shortages and supply disruptions (1)
- Sunscreens (1)
- Weight loss products (1)
Type of content
Search
8 result(s) found, displaying 1 to 8
-
News articlesThe Generic Medicines Work-Sharing Initiative has updated its Operational Procedures document and Expression Of Interest form.
-
News articlesA warning to social media influencers and advertisers not to advertise this prescription medicine.
-
News articlesThe Pharmacovigilance Inspection Program (PVIP) Risk Assessment Survey is now open until 18 December 2022 for medicine sponsors to complete.
-
News articlesThe TGA approved Moderna Australia’s application to transition its COVID-19 vaccine, SPIKEVAX (elasomeran), from provisional to full registration.
-
Media releasesTGA has released over 95 batches of influenza vaccine, consisting of over 16.8 million doses, for supply in Australia for the 2022 influenza season.
-
Regulatory decision noticesThe TGA has provisionally approved the Pfizer Australia Pty Ltd COVID-19 vaccine, COMIRNATY, for use as a booster in individuals aged 12 to 15 years old.
-
Regulatory decision noticesThis instrument is the Therapeutic Goods (Poisons Standard) (COVID-19 Treatment—Merck Sharp and Dohme) (Molnupiravir) Labelling Exemption 2022.
-
Regulatory decision noticesThis labelling exemption is granted under section 1.5.5 of Part 2 of the current Poisons Standard.